泰瑞布一般医疗中心

2022年7月11日

彼得失败,医学博士,主任的结构性心脏程序泰瑞布一般医学中心,经导管心房内的霍,路易斯安那州,解释了使用分流术治疗心脏衰竭。失败是最近的首席研究员Corvia心房内分流装置试验。最后的数据提出了从600病人减少LAP-HF试验二世美国关键试验技术和心力衰竭治疗(阻)2022年2月会议。一个心房分流装置的位置不会降低心力衰竭的总速率事件或改善患者的总体人口的健康状况。然而,试验研究确定了应答器组这首开先河的植入式心脏衰竭治疗。失败表示,这可能帮助其他inter-atrial分流设备开发或在临床试验中。他说病人选择似乎是一个重要组成部分,它不是一个适用于所有患者的治疗。微调病人选择过程可能会显示改善的结果。Corvia说的整体结果审判是中立的,但是数据显示患者正常锻炼肺血管阻力(PVR)和无起搏器代表这种技术的应答器组。失败,另一个研究的作者说,这些患者重要的临床效益来自分流治疗,使心房分流第一植入式治疗证明有效性在心力衰竭患者保存射血分数(HFpEF)。 The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of LAP in symptomatic HF patients. It was granted Breakthrough Device designation by the FDA in 2019. It is available for sale in the European Union. Similar intra-atrial shunt devices have been developed by Noya, Occlutech and VWave. Another approach to this concept of therapy was developed by Alleviant, which uses a catheter to open a hole between the left and right atria without the use of a stent support device. Fail said in animal studies these unsupported shunts have stayed open. The idea of the shunt is it forms a passage the that enables the left atrium to decompress at rest and during physical activity, with the aim of lowering left atrial pressure in HF patients. Related Intra-atrial Shunt Content: